Adjuvant Chemo in High-Risk Localized Prostate Cancer

June 2, 2015

This video examines a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.

In this video, Howard M. Sandler, MD, of Cedars-Sinai Medical Center in Los Angeles, discusses a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.

Dr. Sandler presented results of the trial at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.